{"id":"https://openalex.org/W4362481301","doi":"https://doi.org/10.1158/2159-8290.c.6546378.v1","title":"Data from The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma","display_name":"Data from The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362481301","doi":"https://doi.org/10.1158/2159-8290.c.6546378.v1"},"language":"en","primary_location":{"id":"doi:10.1158/2159-8290.c.6546378.v1","doi":"https://doi.org/10.1158/2159-8290.c.6546378.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.c.6546378.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2159-8290.c.6546378.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040149772","display_name":"Nicole R. Infarinato","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicole R. Infarinato","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103048363","display_name":"Jin H. Park","orcid":"https://orcid.org/0000-0001-7017-4979","observed_orcids":["https://orcid.org/0000-0001-7017-4979"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jin H. Park","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053226567","display_name":"Kateryna Krytska","orcid":"https://orcid.org/0009-0009-8402-8687","observed_orcids":["https://orcid.org/0009-0009-8402-8687"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kateryna Krytska","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019240347","display_name":"Hannah T. Ryles","orcid":"https://orcid.org/0000-0001-5126-9075","observed_orcids":["https://orcid.org/0000-0001-5126-9075"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hannah T. Ryles","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102864493","display_name":"Renata Sano","orcid":"https://orcid.org/0000-0001-9630-3388","observed_orcids":["https://orcid.org/0000-0001-9630-3388"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Renata Sano","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109498052","display_name":"Katherine M. Szigety","orcid":"https://orcid.org/0000-0001-9754-6381","observed_orcids":["https://orcid.org/0000-0001-9754-6381"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katherine M. Szigety","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017202683","display_name":"Yimei Li","orcid":"https://orcid.org/0000-0001-9067-6992","observed_orcids":["https://orcid.org/0000-0001-9067-6992","https://orcid.org/0000-0002-7046-4316"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yimei Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023840148","display_name":"Helen Y. Zou","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Helen Y. Zou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072732582","display_name":"Nathan V. Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nathan V. Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004738391","display_name":"Tod Smeal","orcid":"https://orcid.org/0009-0000-0320-7451","observed_orcids":["https://orcid.org/0009-0000-0320-7451"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tod Smeal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073959537","display_name":"Mark A. Lemmon","orcid":"https://orcid.org/0000-0002-3379-5319","observed_orcids":["https://orcid.org/0000-0002-3379-5319"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark A. Lemmon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5030496565","display_name":"Ya\u00ebl P. Moss\u00e9","orcid":"https://orcid.org/0000-0002-3463-0399","observed_orcids":["https://orcid.org/0000-0002-3463-0399"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yael P. Moss\u00e9","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":0.9442999958992004,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":0.9442999958992004,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.049400001764297485,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11173","display_name":"Neurofibromatosis and Schwannoma Cases","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/crizotinib-resistance","display_name":"crizotinib resistance","score":0.972000002861023},{"id":"https://openalex.org/keywords/anaplastic-lymphoma-kinase","display_name":"anaplastic lymphoma kinase","score":0.9490000009536743},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.8479999899864197},{"id":"https://openalex.org/keywords/relapsed-refractory-neuroblastoma","display_name":"relapsed/refractory neuroblastoma","score":0.9049999713897705},{"id":"https://openalex.org/keywords/pediatric-cancer","display_name":"childhood cancer","score":0.6169999837875366}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.9966862201690674},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.8327000141143799},{"id":"https://openalex.org/C2778347629","wikidata":"https://www.wikidata.org/wiki/Q4652380","display_name":"ALK inhibitor","level":5,"score":0.7687411308288574},{"id":"https://openalex.org/C2776715637","wikidata":"https://www.wikidata.org/wiki/Q938205","display_name":"Neuroblastoma","level":3,"score":0.7097259759902954},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6110386252403259},{"id":"https://openalex.org/C2775999482","wikidata":"https://www.wikidata.org/wiki/Q18031208","display_name":"ROS1","level":4,"score":0.513398289680481},{"id":"https://openalex.org/C2780225316","wikidata":"https://www.wikidata.org/wiki/Q7131441","display_name":"Panobinostat","level":5,"score":0.5005197525024414},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.40227219462394714},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.28954923152923584},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.17199546098709106},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1519286334514618},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.13932320475578308},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.11641934514045715},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.10434186458587646},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.07894894480705261},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.07686156034469604},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.0},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.0},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/2159-8290.c.6546378.v1","doi":"https://doi.org/10.1158/2159-8290.c.6546378.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.c.6546378.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2159-8290.c.6546378.v1","doi":"https://doi.org/10.1158/2159-8290.c.6546378.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2159-8290.c.6546378.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2103600998","https://openalex.org/W2564097003","https://openalex.org/W2462717932","https://openalex.org/W2337713490","https://openalex.org/W2146396128","https://openalex.org/W171311624","https://openalex.org/W2126298634","https://openalex.org/W4392684544","https://openalex.org/W2404235140","https://openalex.org/W1559319547"],"abstract_inverted_index":{"Abstract":[0],"Neuroblastomas":[1],"harboring":[2,91],"activating":[3],"point":[4],"mutations":[5,21],"in":[6,66,75,88,130,164,175,189,214],"anaplastic":[7],"lymphoma":[8],"kinase":[9],"(ALK)":[10],"are":[11],"differentially":[12],"sensitive":[13],"to":[14,34,106,142],"the":[15,92,104,140,179,184,215],"ALK":[16,44,57,61],"inhibitor":[17,159],"crizotinib,":[18],"with":[19,37,152,168,191],"certain":[20],"conferring":[22],"intrinsic":[23],"crizotinib":[24,65,108,170],"resistance.":[25,171],"To":[26],"overcome":[27,107],"this":[28,187],"clinical":[29,146],"obstacle,":[30],"our":[31],"goal":[32],"was":[33],"identify":[35],"inhibitors":[36],"improved":[38],"potency":[39,55],"that":[40,51,101],"can":[41],"target":[42],"intractable":[43],"variants":[45,58],"such":[46],"as":[47,85,87,114],"F1174L.":[48],"We":[49],"find":[50],"PF-06463922":[52,70,102,144,160],"has":[53,103],"high":[54],"across":[56],"and":[59,78,110,121,174,206],"inhibits":[60],"more":[62],"effectively":[63],"than":[64],"vitro.":[67],"Most":[68],"importantly,":[69],"induces":[71],"complete":[72],"tumor":[73],"regression":[74],"both":[76],"crizotinib-resistant":[77,93],"crizotinib-sensitive":[79],"xenograft":[80,124,133],"mouse":[81],"models":[82,167],"of":[83,150,186],"neuroblastoma,":[84],"well":[86],"patient-derived":[89],"xenografts":[90],"F1174L":[94,120],"or":[95],"F1245C":[96,122],"mutations.":[97],"These":[98],"studies":[99],"demonstrate":[100],"potential":[105],"resistance":[109],"exerts":[111,161],"unprecedented":[112],"activity":[113,163],"a":[115],"single":[116],"targeted":[117],"agent":[118,188],"against":[119],"ALK-mutated":[123,153],"tumors,":[125],"while":[126],"also":[127],"inducing":[128],"responses":[129],"an":[131],"R1275Q":[132],"model.":[134],"Taken":[135],"together,":[136],"these":[137],"results":[138],"provide":[139,178],"rationale":[141,181],"move":[143],"into":[145],"trials":[147],"for":[148,182],"treatment":[149],"patients":[151],"neuroblastoma.":[154,194],"Significance:":[155],"The":[156],"next-generation":[157],"ALK/ROS1":[158],"unparalleled":[162],"ALK-driven":[165],"neuroblastoma":[166],"primary":[169],"Our":[172],"biochemical":[173],"vivo":[176],"data":[177],"preclinical":[180],"fast-tracking":[183],"development":[185],"children":[190],"relapsed/refractory":[192],"ALK-mutant":[193],"Cancer":[195],"Discov;":[196],"6(1);":[197],"96\u2013107.":[198],"\u00a92015":[199],"AACR.":[200],"See":[201],"related":[202],"commentary":[203],"by":[204],"Versteeg":[205],"George,":[207],"p.":[208,220],"20.":[209],"This":[210,217],"article":[211],"is":[212],"highlighted":[213],"In":[216],"Issue":[218],"feature,":[219],"1":[221]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2023-04-05T00:00:00"}